SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors weigh potential earnings surprises against ongoing concerns regarding North American user growth and leadership direction. The community remains deeply divided, with some betting on a turnaround driven by cost-cutting and AR innovation, while others express frustration over historical performance and skepticism toward current management.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant social media engagement and high volatility as investors position themselves ahead of the company's upcoming earnings report. The community is sharply divided, with bulls pointing to new product launches and strategic partnerships as catalysts for a potential short squeeze, while bears argue the company relies on legacy technology and unsustainable growth strategies.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors gear up for the upcoming earnings report, with the community actively debating whether the company's recent strategic shifts and management's guidance can trigger a significant move or a potential short squeeze. Conversations are polarized between bulls betting on a long-term turnaround driven by AI and housing market recovery, and skeptics who remain cautious due to broader economic pressures in the real estate sector.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is driving heavy market activity following a strong quarterly report characterized by record-breaking profitability, triple-digit net income growth, and a positive outlook for its AI-driven advertising platform. While community sentiment is divided, with many investors highlighting the company's massive free cash flow and upcoming e-commerce catalysts, others remain cautious due to volatile price swings, concerns over potential share dilution from shelf offerings, and broader sector-wide selling pressure.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending due to significant attention on its preclinical results for ovarian cancer treatments, with investors actively debating the potential for long-term clinical success versus the risks of share dilution and serial reverse splits. The community remains polarized, with bulls highlighting the collaboration with MD Anderson and a low-float setup, while bears point to the history of reverse splits and the speculative nature of the data.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending due to a wave of positive analyst sentiment and significant contract wins that underscore its pivotal role in the Pentagon's expanding drone and hypersonic defense pipeline. While the community is actively debating the stock's recent volatility and valuation, many remain bullish, pointing to the company's robust backlog and alignment with long-term national security priorities as key reasons for future growth.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending as investors react to a record-profitable quarter, the initiation of a share buyback program, and continued growth from strategic partnerships with Carvana and independent agents. While some community members remain skeptical of the stock's long-term valuation and high-level insider selling, bulls are pointing to strong underwriting discipline and improving net income as signs that the company is effectively navigating its path to sustained profitability.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is seeing intense community debate and volatility as investors weigh strong brand growth against headwinds like increased competition and inventory adjustments. While many bulls view the stock's proximity to 52-week lows as an overreaction to minor market noise, others are focused on upcoming earnings and potential institutional positioning.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to the U.S. Nuclear Regulatory Commission's accelerated approval of the Aurora powerhouse design, a major de-risking milestone that bolsters investor confidence in its modular reactor roadmap. The community is actively debating the stock's potential for a short squeeze given its high short interest, while simultaneously weighing the company's long-term promise as an AI-driven energy play against concerns over its pre-revenue status and insider selling.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is surging following strong quarterly earnings that showcased a record $5.6 billion backlog and a doubling in year-to-date order intake, effectively signaling robust demand from hyperscalers and utility-scale projects. The community is actively debating the stock's momentum, with many highlighting potential short-squeeze dynamics and the long-term strategic value of its energy storage platform for AI-driven data centers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 25,907 shares of the company's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the transaction, the insider...

Entrada Therapeutics (NASDAQ:TRDA) COO Nathan Dowden Sells 15,000 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) COO Nathan Dowden sold 15,000 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating...

Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics (NASDAQ:TRDA) Trading 7.6% Higher - Should You Buy?

Entrada Therapeutics (NASDAQ:TRDA) Stock Price Up 7.6% - What's Next...

Entrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month High  - What's Next?

Entrada Therapeutics (NASDAQ:TRDA) Hits New 52-Week High - Here's What Happened...

Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-entrada-therapeutics-inc-stock...

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat...

Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High - Should You Buy?

Entrada Therapeutics (NASDAQ:TRDA) Sets New 1-Year High - What's Next...

Entrada Therapeutics, Inc. $TRDA Stock Holdings Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 735.0% during the 3rd quarter, according to its most recent 13F filing with the...

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Entrada Therapeutics Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

TRDA
Entrada Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest TRDA News

TRDAEntrada Therapeutics Inc